Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQPH29)

Drug Name
Curcumin Drug Info
Synonyms
curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil
Cross-matching ID
PubChem CID
969516
ChEBI ID
CHEMBL140
CAS Number
CAS 458-37-7
TTD Drug ID
D07SDQ
VARIDT Drug ID
DR00559
INTEDE Drug ID
DR1941

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.62 0.00e+0 44/46 (95.65%) PSMD12;PSMA1;PSMA6;...
Amyotrophic lateral sclerosis 2.37 0.00e+0 267/364 (73.35%) GPX7;CYC1;PSMD12;...
Parkinson disease 2.33 0.00e+0 176/249 (70.68%) UCHL1;TXN;PPIF;...
Prion disease 2.26 0.00e+0 209/273 (76.56%) HSPA1A;HSPA6;HSPA8;...
Steroid hormone biosynthesis 2.23 0.00e+0 43/61 (70.49%) AKR1C2;AKR1C1;AKR1C3;...
Oxidative phosphorylation 2.20 0.00e+0 93/133 (69.92%) ATP6V0B;ATP6V1C1;CYC1;...
Mineral absorption 2.10 0.00e+0 48/60 (80%) HMOX1;MT1M;STEAP1;...
Folate biosynthesis 2.08 0.00e+0 23/26 (88.46%) AKR1C3;AKR1B10;GGH;...
Huntington disease 2.04 0.00e+0 233/306 (76.14%) PPIF;GPX7;CYC1;...
Glutathione metabolism 2.02 0.00e+0 43/57 (75.44%) GCLM;GSR;GPX7;...
Ferroptosis 1.99 7.52e-4 36/41 (87.8%) HMOX1;GCLM;SLC7A11;...
RNA transport 1.94 1.38e-3 128/186 (68.82%) RPP40;EIF5;EEF1A2;...
Cysteine and methionine metabolism 1.91 1.91e-3 43/50 (86%) GCLM;BCAT1;ADI1;...
Spliceosome 1.91 1.77e-3 101/150 (67.33%) HSPA1A;HSPA6;HSPA8;...
Porphyrin and chlorophyll metabolism 1.87 3.31e-3 23/43 (53.49%) HMOX1;CP;UGT2A3;...
Pentose and glucuronate interconversions 1.81 7.75e-3 17/34 (50%) AKR1B10;UGDH;UGT2A3;...
Pathways of neurodegeneration 1.80 9.24e-3 354/475 (74.53%) UCHL1;PPIF;GPX7;...
Aminoacyl-tRNA biosynthesis 1.77 1.06e-2 15/66 (22.73%) GATC;DARS2;QRSL1;...
Ribosome biogenesis in eukaryotes 1.75 1.26e-2 52/108 (48.15%) RPP40;RPP30;IMP4;...
Metabolism of xenobiotics by cytochrome P450 1.73 1.57e-2 49/77 (63.64%) AKR1C1;CBR3;ALDH3A1;...
Drug metabolism 1.71 1.93e-2 78/151 (51.66%) CES1;ALDH3A1;MAOB;...
Thiamine metabolism 1.68 2.29e-2 12/15 (80%) AK1;ACP1;AK2;...
Thermogenesis 1.67 2.66e-2 173/232 (74.57%) CYC1;CPT1A;NDUFAF3;...
Bile secretion 1.66 2.69e-2 68/90 (75.56%) ABCG2;SLC2A1;ABCC2;...
Ribosome 1.64 2.88e-2 113/158 (71.52%) MRPL18;MRPS16;MRPL11;...
RNA polymerase 1.63 3.15e-2 23/31 (74.19%) POLR2I;POLR3G;POLR2K;...
Pyruvate metabolism 1.62 3.64e-2 41/47 (87.23%) ME1;DLAT;ACAT2;...
Protein processing in endoplasmic reticulum 1.60 4.05e-2 127/171 (74.27%) HSPA1A;HSPA6;DNAJB1;...
Homologous recombination 1.59 4.05e-2 35/41 (85.37%) SSBP1;RAD54B;RAD51;...
Alzheimer disease 1.58 4.06e-2 279/369 (75.61%) PPIF;CYC1;PSMD12;...
Allograft rejection -1.63 4.68e-2 32/38 (84.21%) HLA-DPA1;CD40LG;IL5;...
Inflammatory bowel disease -1.64 4.57e-2 58/65 (89.23%) HLA-DPA1;IL5;STAT1;...
Salivary secretion -1.65 4.52e-2 76/93 (81.72%) ATP2B1;PRKCB;CALML5;...
Proteoglycans in cancer -1.66 4.29e-2 172/205 (83.9%) DDX5;PLAU;PLCG1;...
Acute myeloid leukemia -1.67 3.98e-2 66/67 (98.51%) CEBPE;AKT1;CCNA1;...
Viral protein interaction with cytokine and cytokine re... -1.67 4.06e-2 84/100 (84%) CCL20;CCL11;CXCR3;...
Herpes simplex virus 1 infection -1.67 4.22e-2 165/498 (33.13%) PPP1CB;TRAF5;ITGB3;...
AMPK signaling pathway -1.68 4.26e-2 106/120 (88.33%) AKT1;CCNA1;PFKP;...
Other types of O-glycan biosynthesis -1.71 3.73e-2 29/47 (61.7%) POGLUT1;MFNG;RFNG;...
Mucin type O-glycan biosynthesis -1.71 3.90e-2 20/36 (55.56%) GALNT1;GALNT3;GCNT1;...
MicroRNAs in cancer -1.71 3.93e-2 146/310 (47.1%) HDAC5;CCNG1;IKBKB;...
Graft-versus-host disease -1.73 3.60e-2 32/42 (76.19%) HLA-DPA1;IFNG;HLA-E;...
Th1 and Th2 cell differentiation -1.74 3.90e-2 80/92 (86.96%) IL5;STAT1;IFNG;...
Thyroid hormone signaling pathway -1.75 3.40e-2 112/121 (92.56%) PLCG1;RXRB;CREBBP;...
T cell receptor signaling pathway -1.76 3.16e-2 93/104 (89.42%) CD40LG;IL5;IFNG;...
Chemokine signaling pathway -1.76 3.38e-2 163/192 (84.9%) GRK3;GNB3;PTK2;...
Type II diabetes mellitus -1.77 3.65e-2 42/46 (91.3%) CACNA1A;TNF;MAPK9;...
Axon guidance -1.85 1.67e-2 151/182 (82.97%) SEMA3A;PAK1;PTPN11;...
Natural killer cell mediated cytotoxicity -1.89 1.56e-2 99/131 (75.57%) ARAF;IFNG;HLA-E;...
C-type lectin receptor signaling pathway -2.03 2.34e-3 93/104 (89.42%) AKT3;PAK1;PTPN11;...
Phosphatidylinositol signaling system -2.03 2.92e-3 82/97 (84.54%) PIK3C2A;PIK3C3;PI4KB;...
Steroid biosynthesis -2.09 3.90e-3 19/20 (95%) SOAT1;FDFT1;LIPA;...
Inositol phosphate metabolism -2.13 0.00e+0 66/73 (90.41%) PIK3C2A;PIK3C3;PI4KB;...
Notch signaling pathway -2.19 0.00e+0 49/59 (83.05%) DTX4;PTCRA;CREBBP;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 12.5uM - 50uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Bone marrow
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U266 CVCL_0566 Homo sapiens 0.125uM - 10uM 6H, 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 100uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 12.5uM - 50uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 100uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 12.5uM - 50uM 6H
MDST8 CVCL_1400 Homo sapiens 12.5uM - 50uM 6H
NCI-H508 CVCL_1561 Homo sapiens 12.5uM - 50uM 6H
SNU-1040 CVCL_5001 Homo sapiens 12.5uM - 50uM 6H
SNU-C4 CVCL_5008 Homo sapiens 12.5uM - 50uM 6H
SNU-C5 CVCL_5009 Homo sapiens 12.5uM - 50uM 6H
SW480 CVCL_0546 Homo sapiens 12.5uM - 50uM 6H
SW620 CVCL_0547 Homo sapiens 12.5uM - 50uM 6H
SW948 CVCL_0550 Homo sapiens 12.5uM - 50uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 12.5uM - 50uM 6H
HT115 CVCL_1294 Homo sapiens 12.5uM - 50uM 6H
RKO CVCL_0504 Homo sapiens 12.5uM - 50uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 12.5uM - 50uM 6H
SNG-M CVCL_1707 Homo sapiens 12.5uM - 50uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 12.5uM - 50uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 50uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 100uM 3H, 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 100uM 6H, 24H, 48H
DV-90 CVCL_1184 Homo sapiens 12.5uM - 50uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 12.5uM - 50uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 12.5uM - 50uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 12.5uM - 50uM 6H
T3M-10 CVCL_1729 Homo sapiens 12.5uM - 50uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 12.5uM - 50uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 12.5uM - 50uM 6H
HCC515 CVCL_5134 Homo sapiens 0.002uM - 100uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 12.5uM - 50uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 12.5uM - 50uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 12.5uM - 50uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 12.5uM - 50uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 12.5uM - 50uM 6H
OV7 CVCL_1623 Homo sapiens 12.5uM - 50uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 12.5uM - 50uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 12.5uM - 50uM 6H
RMUG-S CVCL_1666 Homo sapiens 12.5uM - 50uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 12.5uM - 50uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 6H, 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 50uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 12.5uM - 50uM 6H
PL-21 CVCL_2161 Homo sapiens 12.5uM - 50uM 6H
SKM-1 CVCL_0010 Homo sapiens 12.5uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 6H, 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 12.5uM - 50uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.002uM - 100uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 12.5uM - 50uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 50uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 12.5uM - 50uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 12.5uM - 50uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 12.5uM - 50uM 6H